<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heidi Theeten</style></author><author><style face="normal" font="default" size="100%">Veronik Hutse</style></author><author><style face="normal" font="default" size="100%">N. Hens</style></author><author><style face="normal" font="default" size="100%">Yavuz,Y.</style></author><author><style face="normal" font="default" size="100%">Hoppenbrouwers,K.</style></author><author><style face="normal" font="default" size="100%">Philippe Beutels</style></author><author><style face="normal" font="default" size="100%">Vranckx,R.</style></author><author><style face="normal" font="default" size="100%">P. Van Damme</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium36577</style></title><secondary-title><style face="normal" font="default" size="100%">Epidemiol.Infect.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">2006</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">ADOLESCENT</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">adults</style></keyword><keyword><style  face="normal" font="default" size="100%">age</style></keyword><keyword><style  face="normal" font="default" size="100%">Age factors</style></keyword><keyword><style  face="normal" font="default" size="100%">AGE GROUP</style></keyword><keyword><style  face="normal" font="default" size="100%">AGE GROUPS</style></keyword><keyword><style  face="normal" font="default" size="100%">Age-group</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">ALL</style></keyword><keyword><style  face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibody</style></keyword><keyword><style  face="normal" font="default" size="100%">Antwerp</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">at</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Child,Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria-Tetanus Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">EVALUATION</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Group</style></keyword><keyword><style  face="normal" font="default" size="100%">health</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulins</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious</style></keyword><keyword><style  face="normal" font="default" size="100%">Institute</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">MEASLE</style></keyword><keyword><style  face="normal" font="default" size="100%">Measles</style></keyword><keyword><style  face="normal" font="default" size="100%">Measles-Mumps-Rubella Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Mumps</style></keyword><keyword><style  face="normal" font="default" size="100%">organization</style></keyword><keyword><style  face="normal" font="default" size="100%">pathogen</style></keyword><keyword><style  face="normal" font="default" size="100%">prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Support</style></keyword><keyword><style  face="normal" font="default" size="100%">risk</style></keyword><keyword><style  face="normal" font="default" size="100%">Rubella</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroepidemiologic Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">serum</style></keyword><keyword><style  face="normal" font="default" size="100%">specific</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">survey</style></keyword><keyword><style  face="normal" font="default" size="100%">Target</style></keyword><keyword><style  face="normal" font="default" size="100%">Targets</style></keyword><keyword><style  face="normal" font="default" size="100%">Tetanus</style></keyword><keyword><style  face="normal" font="default" size="100%">Universities</style></keyword><keyword><style  face="normal" font="default" size="100%">university</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine preventable disease</style></keyword><keyword><style  face="normal" font="default" size="100%">WOMEN</style></keyword><keyword><style  face="normal" font="default" size="100%">world</style></keyword><keyword><style  face="normal" font="default" size="100%">World Health</style></keyword><keyword><style  face="normal" font="default" size="100%">World Health Organization</style></keyword><keyword><style  face="normal" font="default" size="100%">World-health-organization</style></keyword><keyword><style  face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/4/2011</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">504</style></number><volume><style face="normal" font="default" size="100%">139</style></volume><pages><style face="normal" font="default" size="100%">494 - 504</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Susceptibility to vaccine-preventable diseases in Belgium in 2006 was estimated from a serum survey. Immunoglobulins against measles, mumps, rubella (MMR) and diphtheria at all available ages (1-65 years), and against tetanus in &gt;40-year-olds, were measured by ELISA. Age-standardized overall seronegativity for MMR was low (3.9%, 8.0%, 10.4%, respectively). However, the World Health Organization's targets for measles elimination were not met in 5- to 24-year-olds and about 1 in 7 women at childbearing age (15-39 years) were seronegative for rubella. In adults &gt;40 years, tetanus immunity (87.2%, &gt;0.16 IU/ml) largely exceeded diphtheria immunity (20-45%, &gt;0.1 IU/ml). Despite free universal vaccination against MMR for more than 20 years and against diphtheria and tetanus for almost 60 years, our study revealed specific age groups remaining at risk for infection with these pathogens</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">38388</style></custom1><section><style face="normal" font="default" size="100%">494</style></section></record></records></xml>